🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
21Score
DipBuster Score™
$209.90
+$6.07 (+2.98%)
Live price · Source: Yahoo
52-Week Position
$101.00
98% of range
$211.80
Beta
0.908
Market-like
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.908
52W High$211.80
52W Low$101.00
🤖
Not a Dip — Score 21/100
Zone: Sell / Avoid
🔒 Unlock Pro
Valuation
P/E Ratio—
Mkt CapN/A
52W Position98% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.908
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️
Insider Buys
Track director & CEO open-market purchases
📊
Valuation Analysis
P/E, EV/EBITDA, DCF & NCAV metrics
📈
Financial Charts
Revenue, EBITDA, FCF & balance sheet trends
🤖
AI Analysis
Plain-English explanation of every key metric
Sign up free — charts & fundamentals included
Get financial charts, valuation data, dividends & news for DaVita Inc. free. Upgrade to Pro for insider signals & AI analysis.
Sponsored · FCA Regulated Broker
Freetrade
Simple investing app. Free ISA. UK and US stocks. FCA regulated.
Free share when you fund your account
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
1/25
Momentum & Volume
15/25
Quality & Size
5/10
Insider Activity
0/10
Quick Take
⚪
Not a Dip
DipBuster Score: 21/100
📈
Strong recent momentum — price and volume trending in the right direction.
Company Profile
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpati…
Sector
Healthcare
Market
🇺🇸 US
CEO
Javier J. Rodriguez
Staff
76,000 employees
Website